<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-01-09</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-01-09</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>36</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
é¦–æ¬¡åœ¨ä½“å¤–éªŒè¯å°é¼ è®­ç»ƒæ€§å…ç–«çš„äº”æ­¥è¿‡ç¨‹ï¼Œä¸ºç”Ÿç‰©æ ‡å¿—ç‰©å‘ç°å’Œå…ç–«å­¦ç ”ç©¶æä¾›æ–°æ¨¡å‹ï¼ˆGSE290033, GSE290032ï¼‰ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- <strong>è‚¿ç˜¤ç ”ç©¶</strong>ï¼šKDM5è›‹ç™½ä»‹å¯¼åµå·¢ç™Œé¡ºé“‚è€è¯ï¼ˆGSE315077, GSE303889ï¼‰ï¼ŒBORISåŸºå› æ²‰é»˜ä¸ç™Œç—‡æ˜“æ„Ÿæ€§ï¼ˆGSE291162ï¼‰ï¼ŒTfhç»†èƒäºšç¾¤åœ¨æ·‹å·´ç˜¤ä¸­çš„é‰´å®šï¼ˆGSE303738ï¼‰ï¼ŒKLHDC4ä½œä¸ºè‚¾ç»†èƒç™Œçš„é¢„åç”Ÿç‰©æ ‡å¿—ç‰©ï¼ˆGSE315815ï¼‰ï¼Œä»¥åŠè½¬ç§»æ€§ç»“ç›´è‚ ç™Œçš„å•ç»†èƒRNA-seqåˆ†æï¼ˆGSE308920ï¼‰ã€‚<br />
- <strong>å‘è‚²ä¸è¡°è€</strong>ï¼šè¡°è€å°é¼ å¿ƒè„å•ç»†èƒATAC-seqç ”ç©¶æŸ“è‰²è´¨é‡å¡‘ï¼ˆGSE303973ï¼‰ï¼Œä»¥åŠèƒšèƒå‘è‚²ä¸­è½¬å½•è°±å¼‚è´¨æ€§åˆ†æï¼ˆGSE242274ï¼‰ã€‚<br />
- <strong>ç¯å¢ƒé€‚åº”ä¸è¿›åŒ–</strong>ï¼šå¤§è¥¿æ´‹é³‰é±¼çš„è¡¨è§‚é—ä¼ å¯å¡‘æ€§é©±åŠ¨æ±¡æŸ“è€å—æ€§ï¼ˆGSE313975, GSE313974ï¼‰ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- <strong>å•ç»†èƒæµ‹åº</strong>ï¼šå¹¿æ³›åº”ç”¨äºæ­ç¤ºç»†èƒè°±ç³»å¼‚è´¨æ€§ã€è¡°è€å¿ƒè„çš„æŸ“è‰²è´¨é‡å¡‘ã€ä»¥åŠè‚¿ç˜¤å’Œå…ç–«ç»†èƒçš„ç²¾ç»†ç»“æ„ï¼ˆGSE242274, GSE303973, GSE308920, GSE287976ï¼‰ã€‚<br />
- <strong>ç©ºé—´è½¬å½•ç»„å­¦</strong>ï¼šæå‡ºæ–°å‹æ··åˆæ–¹æ³•ç”¨äºç©ºé—´è½¬å½•ç»„å­¦å‘ç°ï¼ˆGSE315411ï¼‰ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹ç©ºé—´è½¬å½•ç»„å­¦å·¥å…·SPLISOSMæ­ç¤ºè„‘ç»„ç»‡å’Œè‚¿ç˜¤ä¸­å‰ªæ¥å¼‚æ„ä½“è°ƒæ§æ–°æœºåˆ¶ï¼› CONCORDå®ç°å¤šç»„å•ç»†èƒRNA-seqæ•°æ®æ•´åˆä¸æ‰¹æ¬¡æ ¡æ­£ï¼Œæ„å»ºè·¨å®éªŒå’Œç‰©ç§çš„ç›¸å¹²ç»†èƒçŠ¶æ€å›¾è°±ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç©ºé—´è½¬å½•ç»„å­¦åˆ†æè„‘ç»„ç»‡å’Œè‚¿ç˜¤å¼‚æ„ä½“ç‰¹å¼‚æ€§æ¨¡å¼<br />
- å•ç»†èƒRNA-seqæ•°æ®æ•´åˆä¸æ‰¹æ¬¡æ ¡æ­£<br />
- çŸ­æ—¶é«˜å¼ºåº¦è¿åŠ¨å¯¹ç™Œç—‡DNAä¿®å¤çš„æ¿€æ´»æ•ˆåº”</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- SPLISOSMï¼šé¦–ä¸ªæ•´åˆç©ºé—´åˆ†è¾¨ç‡çš„å¼‚æ„ä½“æ˜ å°„å·¥å…·<br />
- CONCORDï¼šæ–°å‹æ‰¹æ¬¡æ ¡æ­£ä¸å»å™ªæ–¹æ³•ï¼Œå®ç°è·¨æ•°æ®é›†ç»†èƒçŠ¶æ€æ¯”è¾ƒ</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (33æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE290033 ä½“å¤–æ–¹æ³•è®ºè¯æ˜å°é¼ è®­ç»ƒå…ç–«çš„äº”ä¸ªæ­¥éª¤ï¼šå¯¹ç”Ÿç‰©æ ‡å¿—ç‰©å‘ç°ã€é€‚åº”æ€§å…ç–«ååº”ã€å°é¼ å“ç³»ã€æ ·æœ¬å†·å†»ä¿å­˜å’ŒåŸºå› æ¶ˆèçš„å½±å“ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Maria Gonzalez-Perez ; Jana Baranda ; Leticia Perez-Rodriguez ; Patricia Conde ; Carlos de la Calle-Fabregat ; Marcos J Berges Buxeda ; Alexander Dimitrov ; Javier Arranz ; Sergio Rius-Rocabert ; Alessia Zotta ; Ana Dopazo ; Nikita Poddar ; Xuedi Wang ; Estanislao Nistal-VillÃ¡n ; RaphaÃ«l Duivenvoorden ; Joren Madsen ; David L Williams ; Dan Hasson ; Daniel Ojalvo-Lozano ; Florent Ginhoux ; Luke A.J. O'Neill ; Jordi OchandoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTrained immunity is defined by increased inflammatory cytokine production by macrophages that are sequentially activated by two stimuli, separated by a resting period. The models used to study trained immunity should reflect the definition of this process, which includes five different steps. Here, we developed an in vitro methodology to study trained immunity using murine bone marrow-derived macrophages (BMDM), following sequential stimulation with Î²-glucan and lipopolysaccharide (LPS). Kinetic analysis of cytokine production demonstrated, for the first time, that trained BMDM secrete high levels of tumor necrosis factor (TNF) and interleukin 6 (IL6) following stimulation with Î²-glucan (stimulus 1), compared to unstimulated BMDM (step 1). After a resting period, trained BMDM do not secrete significant levels of these cytokines (step 2), but rapidly produce enhanced levels of TNF and IL6 after secondary stimulation with LPS (stimulus 2), compared to BMDM stimulated with either Î²-glucan (step 3) or LPS (step 4) alone. In addition, the sum of cytokine levels produced by both BMDM stimulated with either Î²-glucan (stimulus 1) or LPS (stimulus 2) individually, was significantly lower than the cytokine levels produced by trained BMDM stimulated with both Î²-glucan and LPS (stimulus 1+2) (step 5). Our findings also demonstrate that trained BMDM produce higher levels of serum amyloid A3 (SAA3) protein due to metabolic and epigenetic reprogramming. Functionally, trained BMDM upregulate the expression of stimulatory molecules such as MHC-II, CD80, CD86, OX40L and PDL1; downregulate the inhibitory molecules ICOSL and CD206; and induce CD4+ and CD8+ T cell proliferation in vitro through a cell contact-dependent mechanism. Our results also revealed strain-specific differences in the training response among mice, the negative impact of cell cryopreservation on trained immunity, and the potential use of genetically modified mice in elucidating mechanisti...<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290033" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE290032 ä½“å¤–æ–¹æ³•è®ºè¯æ˜å°é¼ è®­ç»ƒå…ç–«çš„äº”ä¸ªæ­¥éª¤ï¼šå¯¹ç”Ÿç‰©æ ‡å¿—ç‰©å‘ç°ã€é€‚åº”æ€§å…ç–«ååº”ã€å°é¼ å“ç³»ã€æ ·æœ¬å†·å†»ä¿å­˜å’ŒåŸºå› æ¶ˆèçš„å½±å“ [ATAC-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€ATAC-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Maria Gonzalez-Perez ; Jana Baranda ; Leticia Perez-Rodriguez ; Patricia Conde ; Carlos de la Calle-Fabregat ; Marcos J Berges Buxeda ; Alexander Dimitrov ; Javier Arranz ; Sergio Rius-Rocabert ; Alessia Zotta ; Ana Dopazo ; Nikita Poddar ; Xuedi Wang ; Estanislao Nistal-VillÃ¡n ; RaphaÃ«l Duivenvoorden ; Joren Madsen ; David L. Williams ; Dan Hasson ; Daniel Ojalvo-Lozano ; Florent Ginhoux ; Luke A.J. O'Neill ; Jordi OchandoSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusTrained immunity is defined by increased inflammatory cytokine production by macrophages that are sequentially activated by two stimuli, separated by a resting period. The models used to study trained immunity should reflect the definition of this process, which includes five different steps. Here, we developed an in vitro methodology to study trained immunity using murine bone marrow-derived macrophages (BMDM), following sequential stimulation with Î²-glucan and lipopolysaccharide (LPS). Kinetic analysis of cytokine production demonstrated, for the first time, that trained BMDM secrete high levels of tumor necrosis factor (TNF) and interleukin 6 (IL6) following stimulation with Î²-glucan (stimulus 1), compared to unstimulated BMDM (step 1). After a resting period, trained BMDM do not secrete significant levels of these cytokines (step 2), but rapidly produce enhanced levels of TNF and IL6 after secondary stimulation with LPS (stimulus 2), compared to BMDM stimulated with either Î²-glucan (step 3) or LPS (step 4) alone. In addition, the sum of cytokine levels produced by both BMDM stimulated with either Î²-glucan (stimulus 1) or LPS (stimulus 2) individually, was significantly lower than the cytokine levels produced by trained BMDM stimulated with both Î²-glucan and LPS (stimulus 1+2) (step 5). Our findings also demonstrate that trained BMDM produce higher levels of serum amyloid A3 (SAA3) protein due to metabolic and epigenetic reprogramming. Functionally, trained BMDM upregulate the expression of stimulatory molecules such as MHC-II, CD80, CD86, OX40L and PDL1; downregulate the inhibitory molecules ICOSL and CD206; and induce CD4+ and CD8+ T cell proliferation in vitro through a cell contact-dependent mechanism. Our results also revealed strain-specific differences in the training response among mice, the negative impact of cell cryopreservation on trained immunity, and the potential use of genetically modified mice in elucida...<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290032" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE315077 KDM5è›‹ç™½ä»‹å¯¼åµå·¢ç™Œçš„é¡ºé“‚è€è¯æ€§ã€‚[ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€ChIP-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jung Yoo ; So Hee KwonSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensHigh recurrence and relapse rates of ovarian cancer (OVC) make it one of the deadliest gynecological cancers and the 5th most common cause of death in women. It is well recognized that acquired resistance is accompanied by abnormal alteration of epigenetic regulation, yet there is a lack of in-depth mechanistic study on cisplatin-resistant OVC in epigenetic context. Herein, we investigate the role of lysine lysine demethylase 5 (KDM5) and how its abnormal overexpression correlates with cisplatin resistance and OVC tumor progression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315077" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GSE303973ï¼šåˆ©ç”¨ snATAC æµ‹åºæŠ€æœ¯å¯¹è¡°è€å°é¼ å¿ƒè„è¿›è¡Œæµ‹åºï¼Œä»¥ç ”ç©¶å•ç»†èƒæ°´å¹³çš„æŸ“è‰²è´¨é‡å¡‘ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šagingã€sequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Michail Yekelchyk ; Julian Wagner ; Kathrin StilzSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusTo study chromatin remodelig of the aging mouse heart, hearts from young and gaed mice were taken and nuclei were isolated via FACS. SnATAC Seq was performed using the 10X Genomics kit. Michail Yekelchyk (AG Braun) analysed the data)<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303973" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE242274 å•ç»†èƒæµ‹åºæ­ç¤ºé¢…å¤–åŠ¨é™è„‰ç•¸å½¢ä¸­è½¬å½•ç»†èƒè°±ç³»å¼‚è´¨æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yi Sun ; Ren CaiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensExtracranial arteriovenous malformations (eAVMs) are rare congenital vascular anomalies consisting of abnormal artery-vein bypass with no intervening capillary network and can lead to disability and death. In this study, an integration of two cutting-edge technologies, single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST), was applied to uncover the underlying pathophysiology of eAVMs. Patient-matched eAVM tissue samples and normal tissue control data were analyzed. We identified different cell states of endothelial cells (ECs), perivascular cells and immune cells in eAVMs and characterized their spatial distributions with multiple immunofluorescence staining (mIF), immunostaining and spatial transcriptomics. Dysregulated cell-to-cell interactions among ECs, perivascular cells and immune cells that are associated with disease progression were cataloged. By performing scRNA-seq on 117,360 individual cells, we identified 14 transcriptomically defined cell lineages from eAVMs. We uncovered the presence of MAFB+ nidus ECs. Moreover, mesenchymal activation was observed in ECs, characterized by high expression of POSTN or FN1 and the upregulation of the NOTCH and TGF-Î² pathways. mIF and ST verified the location of MAFB+ nidus ECs and mesenchymal activation of eAVM ECs. We identified transcriptional variation within perivascular cells and the presence of smooth muscleâ€“like pericytes in eAVMs. Ligandâ€’receptor-based cellâ€’cell interaction analysis indicated that Nd ECs might specifically communicate with perivascular cells through the MDK, VEGF, SEMA3 and ANGPT pathways, and this cellular crosstalk was supported by colocalization analysis of spatial transcriptomics. In addition, we found that hypoxia plays an important role in the development of eAVMs, and hyperbaric oxygen therapy (HBOT) was used to treat one large pelvic eAVM. Thus, correcting the hypoxic microenvironment could be a promising therapeutic strategy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE242274" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE313975 è¡¨è§‚é—ä¼ å¯å¡‘æ€§æ˜¯å¤§è¥¿æ´‹é³‰é±¼å¯é—ä¼ æ±¡æŸ“è€å—æ€§çš„é©±åŠ¨å› ç´  [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Mathia Colwell ; Melissa K. Drown ; Nicole Flack ; Carrie Walls ; Christopher Faulk ; Samantha Carrothers ; Emma Weeks ; Caren WeinhouseSeries Type : Expression profiling by high throughput sequencingOrganism : Fundulus heteroclitusHeritable epigenetic adaptation to environmental stressors is a compelling but highly contested possibility. Previously, we showed evidence of a generationally heritable epigenetic memory at the cytochrome P450 1A (CYP1A) gene in wild Atlantic killifish (Fundulus heteroclitus) with evolved tolerance to PAH. This memory leads to blunted induction of CYP1A by PAH; this blunting that protects against polycyclic aromatic hydrocarbon (PAH)-induced cancer. Here, using Oxford Nanopore long-read sequencing in PAH-tolerant and sensitive wild-type embryos, we show that genome-wide, PAH-tolerant embryos showed reduced plasticity in DNA methylation response to PAH vs. PAH sensitive embryos that was not due to mutational loss of CpG sites. Notably, we observed population differences in gene methylation in pathways linked to the PAH tolerance phenotype, including AHR and voltage-gated potassium channel signaling, as well as developmental processes and energy metabolism. Specifically, we observed PAH-induced loss of CYP1A gene body methylation in PAH-sensitive (86% CpG methylation in control, decreased to 63% in exposed), but not -tolerant (84% control, 86% exposed), embryos. We observed similar patterns at CYP1B, CYP1C, and the aryl hydrocarbon receptor repressor, AHRR, which show similarly blunted expression. This genic methylation loss was correlated with decreased levels of natural anti-sense RNA transcripts in cis (cis-NATs), which may regulate transcription of these genes. Our data support the existence of stable epigenetic responses to chronic environmental stressors in a natural experimental setting, with broad implications for natural or directed adaptation strategies for other populations.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313975" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE313974 è¡¨è§‚é—ä¼ å¯å¡‘æ€§æ˜¯å¤§è¥¿æ´‹é³‰é±¼å¯é—ä¼ æ±¡æŸ“è€å—æ€§çš„é©±åŠ¨å› ç´  [ONT é•¿è¯»æµ‹åºï¼›DNA]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Mathia Colwell ; Melissa K. Drown ; Nicole Flack ; Carrie Walls ; Christopher Faulk ; Samantha Carrothers ; Emma Weeks ; Caren WeinhouseSeries Type : OtherOrganism : Fundulus heteroclitusHeritable epigenetic adaptation to environmental stressors is a compelling but highly contested possibility. Previously, we showed evidence of a generationally heritable epigenetic memory at the cytochrome P450 1A (CYP1A) gene in wild Atlantic killifish (Fundulus heteroclitus) with evolved tolerance to PAH. This memory leads to blunted induction of CYP1A by PAH; this blunting that protects against polycyclic aromatic hydrocarbon (PAH)-induced cancer. Here, using Oxford Nanopore long-read sequencing in PAH-tolerant and sensitive wild-type embryos, we show that genome-wide, PAH-tolerant embryos showed reduced plasticity in DNA methylation response to PAH vs. PAH sensitive embryos that was not due to mutational loss of CpG sites. Notably, we observed population differences in gene methylation in pathways linked to the PAH tolerance phenotype, including AHR and voltage-gated potassium channel signaling, as well as developmental processes and energy metabolism. Specifically, we observed PAH-induced loss of CYP1A gene body methylation in PAH-sensitive (86% CpG methylation in control, decreased to 63% in exposed), but not -tolerant (84% control, 86% exposed), embryos. We observed similar patterns at CYP1B, CYP1C, and the aryl hydrocarbon receptor repressor, AHRR, which show similarly blunted expression. This genic methylation loss was correlated with decreased levels of natural anti-sense RNA transcripts in cis (cis-NATs), which may regulate transcription of these genes. Our data support the existence of stable epigenetic responses to chronic environmental stressors in a natural experimental setting, with broad implications for natural or directed adaptation strategies for other populations.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313974" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE291162 äººæºåŒ–å°é¼ æ¨¡å‹ä¸­ç™Œç¾ä¸¸æŠ—åŸBORISå‘è‚²æ²‰é»˜ä¸å®Œå…¨ä¼šä¿ƒè¿›ç™Œç—‡æ˜“æ„Ÿæ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€antigen<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Emma Price ; Victor LobanenkovSeries Type : Genome binding/occupancy profiling by high throughput sequencing ; Expression profiling by high throughput sequencingOrganism : Mus musculusCancer-testis antigens are genes normally restricted to the germline but aberrantly activated in many cancers, where their role in tumorigenesis remains unclear. BORIS (CTCFL), a testis-specific paralog of the chromatin organizer CTCF, is one such antigen that shows limited conservation between humans and mice, complicating in vivo functional studies. Here, we generated humanized mice in which both alleles of the endogenous Boris locus are replaced with the full-length human BORIS gene, including its highly diverged cis-regulatory elements. These fully humanized mice maintain normal fertility, indicating accurate germline expression and preserved BORIS function despite evolutionary divergence. However, unlike the strictly testis-specific expression of mouse Boris, human BORIS escapes complete somatic silencing, producing mosaic expression in a minority of mouse somatic cells. This ectopic expression is associated with reduced survival, increased tumor incidence and a shift of tumor spectrum toward aggressive lymphomas. Transcriptomic and chromatin profiling revealed that ectopic human BORIS reactivates testes-specific genes in the soma, including regulators of meiosis and DNA repair, through direct chromatin binding. This transcriptional reprogramming was consistent across tissues and clonal cell lines, revealing a dominant tissue-independent gene activation program. These findings demonstrate that when human BORIS escapes epigenetic silencing in somatic cells, it connects aberrant germline gene activation with increased cancer susceptibility in vivo.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291162" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE303738 åœ¨è¡€ç®¡å…ç–«æ¯ç»†èƒæ€§ T ç»†èƒæ·‹å·´ç˜¤ (AITL) å°é¼ æ¨¡å‹ä¸­é‰´å®šå‡ºè‚¿ç˜¤æ€§ Tfh æ ·ç»†èƒäºšç¾¤</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šlymphomaã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Saba Mohammaei ; Antoine Bouchard ; Woong-Kyung SuhSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusNodal T-follicular helper cell lymphoma, angioimmunoblastic type (nTFHL-AI, or AITL), is an aggressive peripheral T cell lymphoma without effective treatments. It has been shown that genetic and epigenetic changes lead to the expansion of neoplastic CD4+ T cells originating from T follicular helper (Tfh) cells, which subsequently cause B cell expansion and tumor. However, it remains unclear if the Tfh-like cell populations contain a subset that drive tumor progression and, if so, whether such a subset may have druggable targets. Using a mouse model of AITL driven by heterozygous sanroque mutation (Roquinsan/+), we identified a tumor-enriched Tfh cell subset highly expressing CXCR6 and IL-18 receptor, termed â€œDouble-Expressor (DE) Tfhâ€ cells. DE Tfh cells also expressed higher levels of enhancer of zeste homolog 2 (EZH2). In vitro data indicated that IL-18 and EZH2 are required for the proliferation of DE Tfh cells. Furthermore, DE Tfh cells have a potent capacity to expand B cells when adoptively transferred to lymphopenic recipients. On the other hand, depletion of DE Tfh cells via Ezh2 gene deletion, inhibition of EZH2 (using FDA-approved drug, tazemetostat), or anti-CXCR6 mAb led to tumor regression. These findings may be relevant to a subset of AITL cases since we found that ~20-30% of AITL patient samples have concomittantly elevated expression of CXCR6, IL-18R1, and IFNG. Thus, our study identified a pathogenic Tfh-like subset essential for AITL tumor progression in a mouse model and suggests that identifying and targeting DE Tfh-like subset in AITL patients might be an effective strategy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303738" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE315815 KLHDC4 æ˜¯ä¸€ç§æ–°å‹é¢„åç”Ÿç‰©æ ‡å¿—ç‰©ï¼Œå¯é€šè¿‡ PI3K/AKT ä¿¡å·é€šè·¯é©±åŠ¨é€æ˜ç»†èƒè‚¾ç»†èƒç™Œçš„è‚¿ç˜¤è¿›å±•ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€carcinoma<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : HomoThe clinical significance and molecular mechanisms of KLHDC4 in malignancies, particularly in clear cell renal cell carcinoma (ccRCC), remain poorly understood. In this study, we integrated multi-omics dataâ€”including tran-scriptomic, proteomic, and single-cell RNA sequencingâ€”to systematically evaluate the clinical relevance and func-tional role of KLHDC4, followed by experimental validation. Our results demonstrated that KLHDC4 is significantly upregulated in multiple cancer types and serves as an independent prognostic biomarker for poor survival in ccRCC. KLHDC4 expression was correlated with immune cell infiltration, tumor mutational profiles, and immune check-point expression. Furthermore, KLHDC4 levels predicted response to drug therapies, including immunotherapy and tyrosine kinase inhibitors. Functional experiments showed that KLHDC4 knockdown suppressed proliferation, mi-gration, and invasion in vitro, as well as tumor growth in vivo, whereas its overexpression promoted malignant phenotypes. Mechanistic investigations through RNA sequencing and Western blot analysis indicated that KLHDC4 activates the PI3K/AKT signaling pathway. Rescue assays confirmed that KLHDC4-driven oncogenic effects are partially mediated through this axis. Additionally, molecular docking identified ledipasvir as a potential KLHDC4 inhibitor. Collectively, our findings establish KLHDC4 as a novel prognostic biomarker and therapeutic predictor, highlighting the KLHDC4/PI3K/AKT axis as a potential target for ccRCC treatment.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315815" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 23 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>SPLISOSMâ€”â€”åˆ©ç”¨ç©ºé—´è½¬å½•ç»„å­¦æ•°æ®ç»˜åˆ¶å¼‚æ„ä½“åŠå…¶è°ƒæ§æœºåˆ¶å›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šUsing RNA sequencing with spatial resolution, SPLISOSM maps isoform-specific patterns in brain and tumor tissues, revealing conserved splicing regulation and links to neurological disease...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/splisosm-mapping-isoforms-and-regulatory-mechanisms-from-spatial-transcriptomics-data/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>CONCORDâ€”â€”æ­ç¤ºå•ç»†èƒæ•°æ®é›†ä¸­ä¸€è‡´çš„ç»†èƒçŠ¶æ€å›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šCONCORD unifies batch correction and denoising to reveal coherent cell-state landscapes from RNA sequencing data, enabling high-resolution comparison of single-cell datasets across experiments and species...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/concord-revealing-a-coherent-cell-state-landscape-across-single-cell-datasets/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ä»…ä»…10åˆ†é’Ÿçš„è¿åŠ¨å°±èƒ½å¼•å‘å¼ºå¤§çš„æŠ—ç™Œæ•ˆæœ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA brief, intense workout may do more than boost fitnessâ€”it could help fight cancer. Researchers found that just 10 minutes of hard exercise releases molecules into the bloodstream that switch on DNA repair and shut down cancer growth signals. When these molecules were applied to bowel cancer cells, hundreds of cancer-related genes changed activity. The discovery helps explain how exercise lowers cancer risk and hints at future therapies inspired by movement.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/01/260107225535.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>8</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>7</td>
</tr>
<tr>
<td>sequencing</td>
<td>5</td>
</tr>
<tr>
<td>single-cell</td>
<td>3</td>
</tr>
<tr>
<td>resistance</td>
<td>3</td>
</tr>
<tr>
<td>epigenetic</td>
<td>3</td>
</tr>
<tr>
<td>immunity</td>
<td>3</td>
</tr>
<tr>
<td>spatial</td>
<td>2</td>
</tr>
<tr>
<td>immune</td>
<td>2</td>
</tr>
<tr>
<td>T cell</td>
<td>2</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>2</td>
</tr>
<tr>
<td>carcinoma</td>
<td>2</td>
</tr>
<tr>
<td>spatial transcriptomics</td>
<td>1</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>1</td>
</tr>
<tr>
<td>regex:intestin(e</td>
<td>al)</td>
</tr>
<tr>
<td>aging</td>
<td>1</td>
</tr>
<tr>
<td>RNAseq</td>
<td>1</td>
</tr>
<tr>
<td>metabolism</td>
<td>1</td>
</tr>
<tr>
<td>antigen</td>
<td>1</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (23æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315687" target="_blank" rel="noopener noreferrer">GSE315687 æŠ—CD4è€—ç«­æŠ—ä½“é€šè¿‡æ¿€æ´»CD8+ Tç»†èƒå’ŒæŠ‘åˆ¶è°ƒèŠ‚æ€§Tç»†èƒåœ¨å°é¼ è‚ºçº¤ç»´åŒ–ä¸­å‘æŒ¥æŠ—è‚¿ç˜¤ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308920" target="_blank" rel="noopener noreferrer">GSE308920 AKPSè½¬ç§»æ€§ç»“è‚ ç™Œæ¨¡å‹çš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303889" target="_blank" rel="noopener noreferrer">GSE303889 KDM5 è›‹ç™½ä»‹å¯¼åµå·¢ç™Œçš„é¡ºé“‚è€è¯æ€§ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE222430" target="_blank" rel="noopener noreferrer">GSE222430ï¼šä¸ƒæ°Ÿçƒ·æš´éœ²åè€å¹´å°é¼ è½¬å½•ç»„çš„10å€å•ç»†èƒæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315770" target="_blank" rel="noopener noreferrer">GSE315770ï¼šåœ¨å›ºä½“ç¼è„‚å¹³æ¿ä¸Šï¼ŒäºPDï¼ˆ100 mM NaClï¼‰æ¡ä»¶ä¸‹å¯¹é‡ç”Ÿå‹ç§€ä¸½éšæ†çº¿è™«è¿›è¡ŒRNA-seqåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315766" target="_blank" rel="noopener noreferrer">GSE315766 RNA-seq åˆ†æç§€ä¸½éšæ†çº¿è™«ä¸­ä½é’¾å’Œ pmk-1 è°ƒæ§åŸºå› </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315765" target="_blank" rel="noopener noreferrer">GSE315765 RNA-Seq åˆ†æ Mapk14 æ•²é™¤å’Œ C2C12 ç»†èƒæˆè‚Œåˆ†åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310159" target="_blank" rel="noopener noreferrer">GSE310159 èœ•çš®æ¿€ç´ ä»‹å¯¼çš„è‚ é“ç”Ÿé•¿ä¿ƒè¿›è¥å…»ä¸è‰¯æ¡ä»¶ä¸‹å¾®ç”Ÿç‰©ç¾¤é©±åŠ¨çš„å‘è‚²å¯å¡‘æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303574" target="_blank" rel="noopener noreferrer">GSE303574 ZBTB16æŠ‘åˆ¶åHUVECç»†èƒçš„æ‰¹é‡ATACæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287976" target="_blank" rel="noopener noreferrer">GSE287976 äººç±»å—œç¢±æ€§ç²’ç»†èƒå•ç»†èƒç»„å­¦åˆ†ææ­ç¤ºäº†ä¸¤ä¸ªè½¬å½•ç»„ä¸åŒçš„ç»†èƒç¾¤</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315788" target="_blank" rel="noopener noreferrer">GSE315788 Î²3-è‚¾ä¸Šè…ºç´ èƒ½å—ä½“ä¸‹è°ƒå¯¼è‡´è‚¥èƒ–ç—‡ä¸­è„‚è‚ªç»†èƒå„¿èŒ¶é…šèƒºæŠµæŠ—</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315411" target="_blank" rel="noopener noreferrer">GSE315411 åŒçº¿æ•é±¼ï¼šä¸€ç§ç©ºé—´è½¬å½•ç»„å‘ç°çš„æ··åˆæ–¹æ³•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312325" target="_blank" rel="noopener noreferrer">GSE312325 Grin2b çªå˜å°é¼ çš„å¼‚å¸¸ mRNA å‰ªæ¥å’Œæµ·é©¬ç¥ç»å‘ç”Ÿå—æŸ [RNAseq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295012" target="_blank" rel="noopener noreferrer">GSE295012 ç³–è›‹ç™½éè½¬ç§»æ€§é»‘è‰²ç´ ç˜¤è›‹ç™½B (GPNMB) çš„ç¼ºå¤±ä¼šåŠ å‰§æ„ŸæŸ“æŒ‘æˆ˜æœŸé—´å†…çš®ç»†èƒçš„é€šé€æ€§ã€ä»£è°¢å’Œå­˜æ´»ç‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268636" target="_blank" rel="noopener noreferrer">GSE268636 é›„æ¿€ç´ å—ä½“å‰ªæ¥å˜ä½“è¡¨è¾¾ä¸æŒ½æ•‘æ²»ç–—åå‰åˆ—è…ºç™Œå¤å‘</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315860" target="_blank" rel="noopener noreferrer">GSE315860 DAXX æ§åˆ¶å°é¼ ç²¾å­å‘ç”Ÿè¿‡ç¨‹ä¸­ LINE1 çš„æ²‰é»˜ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315521" target="_blank" rel="noopener noreferrer">GSE315521 ä¹³é…¸ä»‹å¯¼çš„ KRT15 å’Œ GPR68 ä¹‹é—´çš„ç›¸äº’ä½œç”¨é©±åŠ¨ ECRSwNP ä¸­çš„ 2 å‹å…ç–«ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315518" target="_blank" rel="noopener noreferrer">GSE315518 è¾¾èŠ™å¦®æ±€é€šè¿‡è°ƒèŠ‚DDIT3ç›¸å…³çš„åº”æ¿€ååº”ï¼Œå¢å¼ºè‚ç»†èƒç™Œç»†èƒå¯¹åŒ–ç–—è¯ç‰©çš„æ•æ„Ÿæ€§å¹¶æŠ‘åˆ¶æ¶æ€§è¡¨å‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312105" target="_blank" rel="noopener noreferrer">GSE312105 è¯„ä¼°è¡¨è§‚é—ä¼ æŠ‘åˆ¶å‰‚å¯¹è½¬ç§»æ€§ç±»å™¨å®˜å‘éè½¬ç§»æ€§ç±»å™¨å®˜æŸ“è‰²è´¨ç»“æ„é€†è½¬çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285789" target="_blank" rel="noopener noreferrer">GSE285789 å‰åˆ—è…ºç™Œä¸­ TGF-Î² è¯±å¯¼çš„ M2 æåŒ– TAM æ¥æºçš„å¤–æ³Œä½“ miRNA çš„ä½œç”¨å’Œæœºåˆ¶ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283937" target="_blank" rel="noopener noreferrer">GSE283937 é«˜ MAPKã€ä½ WNT ç»†èƒçŠ¶æ€é©±åŠ¨ç»“ç›´è‚ ç™Œè½¬ç§»æ‰©æ•£</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283935" target="_blank" rel="noopener noreferrer">GSE283935 è½¬ç§»æ€§ç»“ç›´è‚ ç™Œè‚¿ç˜¤ä¸­ MAPK å’Œ Wnt ä¿¡å·é€šè·¯çš„å·®å¼‚å¯Œé›†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252763" target="_blank" rel="noopener noreferrer">GSE252763 äººç±»é¼»è…”æ°”é“ä¸Šçš®ç»†èƒåŸ¹å…»ç‰©çš„ RNA æµ‹åºï¼ˆå¯¹ç…§ç»„å’Œç»“èŠ‚ç—…ç»„ï¼‰</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-08 21:40</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>